Healthcare provider profile · identity verified

Maha Alchaer, MD

Allopathic & Osteopathic Physicians|Family Medicine · ALLENTOWN, PA · NPI 1164603122

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Maha Alchaer, MD received $45.00 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$45.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$45.00	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$45.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	91	18
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	65	13

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	747	167
Levothyroxine Sodium	Levothyroxine Sodium	437	81
Omeprazole	Omeprazole	355	76
Amlodipine Besylate	Amlodipine Besylate	277	62
Gabapentin	Gabapentin	269	67
Lisinopril	Lisinopril	260	46
Losartan Potassium	Losartan Potassium	258	56
Fluticasone Propionate	Fluticasone Propionate	251	75
Simvastatin	Simvastatin	235	41
Pantoprazole Sodium	Pantoprazole Sodium	219	48
Albuterol Sulfate Hfa	Albuterol Sulfate	197	57
Ezetimibe	Ezetimibe	191	43
Metformin Hcl	Metformin Hcl	153	38
Hydrochlorothiazide	Hydrochlorothiazide	150	32
Metoprolol Tartrate	Metoprolol Tartrate	137	27
Montelukast Sodium	Montelukast Sodium	137	26
Metformin Hcl Er	Metformin Hcl	125	28
Metoprolol Succinate	Metoprolol Succinate	124	26
Alendronate Sodium	Alendronate Sodium	122	23
Tamsulosin Hcl	Tamsulosin Hcl	116	23
Sertraline Hcl	Sertraline Hcl	107	25
Eliquis	Apixaban	106	21
Rosuvastatin Calcium	Rosuvastatin Calcium	104	35
Jardiance	Empagliflozin	91	18
Furosemide	Furosemide	89	21
Potassium Chloride	Potassium Chloride	85	18
Famotidine	Famotidine	83	21
Pravastatin Sodium	Pravastatin Sodium	82	17
Breo Ellipta	Fluticasone/Vilanterol	77	suppressed
Farxiga	Dapagliflozin Propanediol	71	18
Trulicity	Dulaglutide	65	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	61	12
Alprazolam	Alprazolam	56	14
Diclofenac Sodium	Diclofenac Sodium	56	35
Methylprednisolone	Methylprednisolone	55	48
Clopidogrel	Clopidogrel Bisulfate	54	14
Olmesartan Medoxomil	Olmesartan Medoxomil	52	14
Allopurinol	Allopurinol	50	15
Dicyclomine Hcl	Dicyclomine Hcl	49	suppressed
Nifedipine Er	Nifedipine	49	11
Atenolol	Atenolol	46	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	46	suppressed
Methocarbamol	Methocarbamol	44	14
Escitalopram Oxalate	Escitalopram Oxalate	41	suppressed
Fenofibrate	Fenofibrate	41	suppressed
Trazodone Hcl	Trazodone Hcl	40	14
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	38	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	38	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	38	suppressed
Naproxen	Naproxen	34	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Fenofibrate	Fenofibrate,micronized	33	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Azithromycin	Azithromycin	31	25
Carvedilol	Carvedilol	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	30	suppressed
Ibuprofen	Ibuprofen	30	suppressed
Meclizine Hcl	Meclizine Hcl	29	14
Ondansetron Hcl	Ondansetron Hcl	29	13
Pregabalin	Pregabalin	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Lidocaine	Lidocaine	27	suppressed
Telmisartan	Telmisartan	27	suppressed
Hydrocortisone	Hydrocortisone	26	20
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Mupirocin	Mupirocin	25	13
Ozempic	Semaglutide	25	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Cephalexin	Cephalexin	23	22
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Methimazole	Methimazole	23	suppressed
Clonazepam	Clonazepam	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	16
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Valsartan	Valsartan	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	21
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	21	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Prolia	Denosumab	20	13
Nystatin	Nystatin	18	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	17	suppressed
Novofine 32	Pen Needle, Diabetic	17	suppressed
Diltiazem Hcl	Diltiazem Hcl	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	16	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	16	suppressed
Premarin	Estrogens, Conjugated	16	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Linzess	Linaclotide	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Torsemide	Torsemide	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	14	suppressed
Glipizide	Glipizide	14	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	13	suppressed
Econazole Nitrate	Econazole Nitrate	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Prednisone	Prednisone	13	11
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	13	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Colchicine	Colchicine	11	suppressed
Diclofenac Potassium	Diclofenac Potassium	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Jantoven	Warfarin Sodium	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$45.00 · 1 records	Lilly USA, LLC	—	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error